Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562781 | 1.00 | ACHE (0.61) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL2466607 | 0.88 | METAP1 (0.53) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL6881129 | 0.87 | ACHE (0.63) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL7771760 | 0.87 | ACHE (0.63) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL6383092 | 0.86 | ALDH1A1 (0.70) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL345475 | 0.86 | ACHE (0.51) | ACHEMETAP1 | |
| SCHEMBL17515294 | 0.84 | ACHE (0.55) | ACHEMETAP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL7222116 | 0.83 | ACHE (0.49) | ACHEMETAP1KDM4EMAPT | |
| SCHEMBL23731241 | 0.82 | KDM4E (0.49) | ACHEKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL4015424 | 0.82 | ACHE (0.56) | ACHEKDM4EMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9376384-B2 | Diaryliodonium salt | UBE INDUSTRIES, LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9376384-B2 | Diaryliodonium salt | UBE INDUSTRIES, LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20160046566-A1 | DIARYLIODONIUM SALT | UBE INDUSTRIES, LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046566-A1 | DIARYLIODONIUM SALT | UBE INDUSTRIES, LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2670245-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | The Scripps Research Institute (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106569-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | BOGER DALE L (US) | 2012-08-09 | — | — | WO | disclosed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005121137-A1 | ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS | BRANDEIS UNIVERSITY (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1047674-B1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | EISAI CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-0700905-B1 | Tricyclic pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-5561150-A | 1-AMINOALKYL-1,4-DIHYDROINDENO(2,1-C)PYRAZOLES OR 1H-BENZ(G)INDAZOLES; SEROTONIN RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM, PSYCHOLOGICAL AND GASTROINTESTINAL DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0700905-A1 | Tricyclic pyrazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1996-03-13 | — | — | EP | disclosed |
| US-4939160-A | Nootropic agents | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| US-4833169-A | MEMORY ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046566-A1 | DIARYLIODONIUM SALT | AGTR2, KCNA5, AGTR1 | ACHE 4511/4885METAP1 2799/4885KDM4E 1145/4885 |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | ALDH3A1, NQO1, DERA | ACHE 756/4885METAP1 1441/4885KDM4E 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.